Search
PF-5212372
go.drugbank.com/drugs/DB19212InvestigationalPF-5212372 is under investigation in clinical trial NCT02795832 (A Study to Determine the Safety & Efficacy of ZPL-5212372 in Healthy Subjects and in Subjects With Atopic Dermatitis).
Categories: Phospholipase A2 InhibitorsNizubaglustat
go.drugbank.com/drugs/DB21603InvestigationalNizubaglustat has a monoisotopic molecular weight of 433.23 Da. … Nizubaglustat is a small molecule drug. The usage of the INN stem '-glustat' in the name indicates that Nizubaglustat is a ceramide glucosyltransferase inhibitor.
Synonyms: AZ-3102Dibromothymoquinone
go.drugbank.com/drugs/DB04646ExperimentalAt higher concentrations, it acts as an electron acceptor, intercepting electrons either before or at the site of its inhibitory activity. [PubChem] … At low concentrations, this compound inhibits reduction of conventional hydrophilic electron acceptors, probably acting as a plastoquinone antagonist.
Difamilast
go.drugbank.com/drugs/DB14987ApprovedInvestigational[L56052, A275420] This skin disease occurs most frequently in children and can have an onset as early as within the first 2 years of life. … [L55042, A275424, A275420] As difamilast's mechanism of action involves the inhibition of PDE4, the inhibition leads to an increase in intracellular cyclic AMP and a subsequent decrease in the production
Vayarin
go.drugbank.com/drugs/DB09328ApprovedA slow response time of 12 weeks is an impediment to successful management of ADHD as only 41.6% of subjects prescribed Vayarin remained compliant for the duration of the study. … Vayarin is a novel therapy for ADHD that appears to be effective in several studies [L1501, L1502, L1503].
Etuvetidigene Autotemcel
go.drugbank.com/drugs/DB17593ApprovedInvestigational[L54693] WAS is a rare X-linked disorder caused by a mutation in the gene encoding the WAS protein, leading to a compromised immune system. … Etuvetidigene autotemcel is an autologous gene therapy which includes hematopoietic stem cells (HSCs) that have been genetically modified ex vivo.
Avalglucosidase alfa
go.drugbank.com/drugs/DB16099ApprovedInvestigationalAvalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe disease, a rare inherited neuromuscular disorder caused by the deficiency of the alpha-glucosidase … [L35160] Late-onset Pompe disease is associated with a range of debilitating physical symptoms, such as progressive muscle weakness, including respiratory muscle weakness, and loss of motor function.
Anisotropine methylbromide
go.drugbank.com/drugs/DB00517ApprovedAnisotropine methylbromide is a quaternary ammonium compound. Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. … Depending on the dose, anisotropine methylbromide may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant
Synonyms: Metilbromuro de octatropinaVotucalis
go.drugbank.com/drugs/DB05032InvestigationalIt is a topically delivered small protein that acts as an anti-inflammatory agent.
Tegafur-uracil
go.drugbank.com/drugs/DB09327ApprovedTegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4. … It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.